MedTrace Logo

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

NCT05578222 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-10-13

No results posted yet for this study

Summary

This clinical trial aims to evaluate the efficacy and safety of pembrolizumab in the first-line treatment of advanced NSCLC complicated with COPD and its influence on the course of COPD, so as to provide prospective clinical evidence for immunotherapy of NSCLC complicated with COPD in China and to guide clinical application.

Conditions

  • NSCLC With COPD

Interventions

DRUG

Pembrolizumab

Pembrolizumab, 200mg i.v. gtt,D1,Q3W,

Sponsors & Collaborators

  • Tianjin Chest Hospital

    lead OTHER

Principal Investigators

  • JianWen Qin · No. 261, Taierzhuang South Road, Jinnan District, Tianjin, Tianjin Chest Hospital.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2023-12-12
Completion
2024-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05578222 on ClinicalTrials.gov